> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Insmed Stock Soars 17%, Adding $3.6 Billion, As It Lifts Sales Forecasts For Its Two Drugs
- URL: https://www.bullished.co/insmed-stock-soars-17-adding-3-6-billion-as-it-lifts-sales-forecasts-for-its-two-drugs-feb43140/
- Published: 2026-10-29T14:37:42.000Z
- Updated: 2026-10-29T14:37:42.000Z
- Description: Insmed raised the low end of 2026 sales forecasts for Brinsupri and Arikayce, and third-quarter revenue rose 268.4% from a year earlier.
- Author: Matteo Parrino
- Tags: Markets, INSM, Industry: Healthcare

[Insmed](https://www.bullished.co/tag/insm/) shares [climbed 16.89% to $113.36](https://finance.yahoo.com/healthcare/articles/insmed-insm-reports-q3-loss-113507941.html?.tsrc=rss&ref=bullished.co) in Thursday trading, as of 10:36 a.m. ET, adding $3.6 billion in market value, on the day the company lifted the low end of its 2026 sales forecasts for Brinsupri and Arikayce. The biopharmaceutical company also launched Brinsupri in Japan, according to an [8-K](https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500%5F8k.htm?ref=bullished.co).

## A revenue surge, a narrower loss

Third-quarter revenue reached [$524.4 million](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000047/insm-20260930.htm?ref=bullished.co), up 268.4% from a year earlier. The net loss was [$100.3 million](https://finance.yahoo.com/healthcare/articles/insmed-q3-earnings-snapshot-110652398.html?ref=bullished.co), the company reported.

Brinsupri revenue was [$400.1 million](https://seekingalpha.com/news/4660061-insmed-gaap-eps-of-0%5F46-misses-by-0%5F08-revenue-of-524%5F4m-beats-by-24%5F92m?ref=bullished.co) for the quarter, up 29% from the second quarter, the company said.

## Two respiratory drugs

Insmed develops and sells treatments for serious diseases. Brinsupri, a once-daily tablet for non-cystic fibrosis bronchiectasis, a chronic lung disease, was approved in the US in August 2025 and in the European Union in November 2025, according to the company's annual report. Arikayce is an inhaled antibiotic for a rare, often chronic lung infection caused by MAC.

The company's pipeline includes an inhaled therapy for pulmonary hypertension and gene therapies for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.

## A rebound from a steep slide

Before Thursday, the stock had fallen 18% over the previous month and sat 54% below its highest close of the past year, set on Dec. 1, 2025\. Shares were [down about 44% year to date](https://finance.yahoo.com/healthcare/articles/insmed-insm-reports-q3-loss-113507941.html?.tsrc=rss&ref=bullished.co) as of Wednesday's close, while the S&P 500 was up about 13%.

Thursday's rally is the third straight daily gain. The stock was on pace for its biggest one-day gain since Aug. 6, when it rose 33.9%. Its market value in Thursday pre-market trading, before the session's gains, was $21.1 billion.

Thursday's session put the stock on pace for its largest one-day gain since the 33.9% surge on Aug. 6.

### Sources

- [Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates](https://finance.yahoo.com/healthcare/articles/insmed-insm-reports-q3-loss-113507941.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance](https://uk.finance.yahoo.com/quote/INSM/?ref=bullished.co) — Yahoo Finance
- [12 Health Care Stocks Moving In Thursday's Pre-Market Session](https://www.benzinga.com/trading-ideas/movers/26/10/62691455/12-health-care-stocks-moving-thursday-s-pre-market-session?ref=bullished.co) — benzinga.com
- [Insmed: Q3 Earnings Snapshot](https://finance.yahoo.com/healthcare/articles/insmed-q3-earnings-snapshot-110652398.html?ref=bullished.co) — Associated Press
- [Insmed GAAP EPS of -$0.46 misses by $0.08, revenue of $524.4M beats by $24.92M (INSM:NASDAQ)](https://seekingalpha.com/news/4660061-insmed-gaap-eps-of-0%5F46-misses-by-0%5F08-revenue-of-524%5F4m-beats-by-24%5F92m?ref=bullished.co) — seekingalpha.com
- [The company's filing (Insmed)](https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500%5F8k.htm?ref=bullished.co) — SEC filing
- [Insmed — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1104506/000110450626000047/insm-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Insmed

- [Insmed Third-Quarter Revenue Hits $524.4 Million, And It Lifts The Floor On 2026 Sales Guidance For Both Drugs](https://www.bullished.co/insmed-third-quarter-revenue-hits-524-4-million-and-it-lifts-the-floor-on-2026-sales-b5f4d5cc/)
- [Insmed Says It Won't Build A Traditional European Sales Operation For BRINSUPRI](https://www.bullished.co/insmed-says-it-wont-build-a-traditional-european-sales-operation-for-brinsupri-7bd53000/)
- [Insmed Names Ex-Sanofi CEO Paul Hudson And Verily Health CFO Utpal Koppikar To Its Board](https://www.bullished.co/insmed-names-ex-sanofi-ceo-paul-hudson-and-verily-health-cfo-utpal-koppikar-to-its-board-26c095be/)

[All Insmed (INSM) coverage →](https://www.bullished.co/tag/insm/)